Healthy adults
Conditions
Interventions
Ingestion of two capsules containing Low molecular Chondroitin Sulfate Origosaccharides (100 mg/day) daily for 8 weeks
Ingestion of two placebo capsules daily for 8 weeks
Sponsors
Hokkaido Information University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects with knee joint pain. 2. Subjects who agree to participate in the current study with a written informed consent.
Exclusion criteria
Exclusion criteria: 1. Subjects who are under treatment and medication for osteoarthritis (knee, the base of the foot, elbow, shoulder, etc.). 2. Injured subjects with problems in daily life. 3. Subjects who are under treatment and medication of rheumatoid arthritis (RA) or subjects who are suspected to have RA (MMP-3>=121 ng/ml (men), MMP-3>=59.7 ng/ml (women)). 4. Subjects who are suspected to have secondary arthrosis (autoimmune disease, gout, bone fracture in the lower body, surgical history in the lower body, injury of ligament and meniscus, dislocation, congenital abnormality of joint function, etc.). 5. Subjects regularly take anticoagulants, antiplatelet agents or NSAIDs. 6. Subjects with serious cerebrovascular, cardiac, hepatic, renal, and / or gastrointestinal diseases, or affected with an infectious disease which is required to report to the authorities. 7. Subjects who have a major surgical history related to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 8. Subjects with unusually high and/or low blood pressure or abnormal hematological data. 9. Subjects with serious anemia. 10. Pre- or post-menopausal subjects having complaints of obvious physical changes. 11. Subjects who are at risk of having allergic reactions to drugs or foods (especially fish or wheat). 12. Subjects regularly take medicine, functional foods and/or supplements which would affect the joint function. 13. Heavy smokers, alcohol addicts or subjects with irregular lifestyle. 14. Subjects who donated either 400ml whole blood within 12 weeks (men) /16 weeks (women) or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to this study. 15. Subjects who are pregnant or expected to be pregnant, or lactating during the study. 16. Subjects who participate in other clinical trials within the last one month prior to the current clinical trial. 17. Any other medical reasons judged by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Japanese Knee Osteoarthritis Measure 4 weeks and 8 weeks after beginning ingestion of test meals | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS questionnaire for knee pain and skin condition, CRP and locomotive syndrome risk test,C2C, CP2,C2C/CP2 ratio | — |
Countries
Japan
Contacts
Public ContactDir. Prof. Jun NISHIHIRA, M.D., Ph.D.
Hokkaido Information University Center of Health Information Science
Outcome results
None listed